Neurologie: De nouveaux médicaments pour le traitement de la

981
HIGHLIGHTS 2014
Neurologie:
De nouveaux médicaments pour le traitement de la
sclérose en plaques récurrente-rémittente (SEP RR)


      

 
 



      



     


    



        







   




     


    


×

    

  

    

      
     

 
     
     



    

     







   
      






   


    ×  

 




   

   
      

β


 
κ




    


     

β
Christian P. Kamm
Les auteurs ont
reçu, au cours des
années passées,
le soutien nancier
des entreprises
et fondations
suivantes, actives
dans le domaine
de la sclérose en
plaques, pour
leurs formations,
exposés,
consulta tions et
projets de
recherches:
Bayer, Biogen
Idec, Genzyme,
Merck-Serono,
Novartis, Roche,
Teva ainsi que la
Société suisse
de la sclérose en
plaques. Departement Neurologie, Inselspital, Universitätsspital
und Universität, Bern

HIGHLIGHTS 2014
 982



    



    
     
 
   




   
  




        




  




       

 

      



 









 
 



 

      








       





  
      

Correspondance:





Christian.Kamm[at]insel.ch
Référence
       

Traitement de
premièreinten�on Traitement de
deuxièmeinten�on Traitement de troisième
inten�on
SEP hautement ac�ve
Natalizumab
Diméthyl
fumarate
Fingolimod
Traitement non mis sur le
marché(CH)
Alemtuzumab
Rituximab
Daclizumab notamment
Transplanta�on autogène de
cellulessouches
Interféronβ
Acétate de
gla�ramère
Natalizumab
(Mitoxantron)
Natalizumab
(Mitoxantron)
Tériflunomide
Diméthylfumarate
Fingolimod
Effet secondaire
Effet secondaire/
Ac�vité de la
maladie
Effet secondaire
Ac�vité
Ac�vité Ac�vité
Ac�vité
Effet secondaire/
Ac�vité de la
maladie
Ac�vité
de la
maladie
Ac�vité/effets secondaires/virus JV posi�f
Figure 1
Schéma thérapeutique de la sclérose en plaques récurrente-rémittente.







1 / 2 100%
La catégorie de ce document est-elle correcte?
Merci pour votre participation!

Faire une suggestion

Avez-vous trouvé des erreurs dans linterface ou les textes ? Ou savez-vous comment améliorer linterface utilisateur de StudyLib ? Nhésitez pas à envoyer vos suggestions. Cest très important pour nous !